SRL
SABS icon

Scientech Research LLC’s SAB Biotherapeutics SABS Stock Holding History

Scientech Research LLC’s Portfolio SABS Stock Details SABS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$68K Buy
17,446
+6,630
+61% +$24.7K 0.06% 188
2026
Q1 		$41.4K Buy
+10,816
New +$43.1K 0.03% 420

Other funds holding SABS

Caligan Partners
Caligan Partners New York $2.13B AUM 758.65% 1-Year Est. Return
Vivo Capital
Vivo Capital Palo Alto, California $1.1B AUM 799.93% 1-Year Est. Return
Perceptive Advisors
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return
RA Capital Management
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $80.2B AUM 51.53% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Commodore Capital
Commodore Capital New York $1.68B AUM 375.52% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

Scientech Research LLC's SABS Position: Q2 2026 in Review

Scientech Research LLC increased its SAB Biotherapeutics (SABS) stake by 61% in Q2 2026, buying an estimated $24.7K and bringing the position to 17,446 shares worth $68K. The position accounts for 0.06% of the portfolio, ranked #188.

Scientech Research LLC first reported a position in SABS in Q1 2026 and has held it in 2 quarters since. 87 funds tracked by Wall St. Rank hold SABS as of Q2 2026.

  • Scientech Research LLC held 17,446 shares of SAB Biotherapeutics worth $68K as of Q2 2026.
  • Scientech Research LLC bought 6,630 SAB Biotherapeutics shares in Q2 2026, an estimated $24.7K.
  • SAB Biotherapeutics made up 0.06% of Scientech Research LLC's portfolio in Q2 2026, its #188 holding.
  • Scientech Research LLC first reported a position in SAB Biotherapeutics in Q1 2026 and has held it in 2 quarters since.
  • 87 funds tracked by Wall St. Rank held SAB Biotherapeutics as of Q2 2026.

Based on Scientech Research LLC's 13F filing for Q2 2026, filed 14 Aug 2026.